Exenatide in type 2 diabetes

The Lancet

Volumn 376, Issue 9746, 2010, Pages 1052-1053

  Verzegnassi, Federico ^a   Chinello, Matteo ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INSULIN GLARGINE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLARGINE; INSULIN; LONG ACTING INSULIN; PEPTIDE; VENOM;

ADJUVANT THERAPY; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HEALTH STATUS; HEART RATE; HUMAN; LETTER; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CALORIC INTAKE; DIABETES MELLITUS, TYPE 2; QUALITY OF LIFE;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; PEPTIDES; QUALITY OF LIFE; VENOMS;

EID: 77957195489     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61485-7     Document Type: Letter

References (5)

1. M Diamant, L Van Gaal, S Stranks Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 375 2010 2234 2243
2. 1c in people with type 2 diabetes: a retrospective cohort study Lancet 375 2010 481 489
3. H Florez, J Luo, S Castillo-Florez Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes Postgrad Med 122 2010 112 120
4. MT Schram, CA Baan, F Pouwer Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium Curr Diabetes Rev 5 2009 112 119
5. WB Kannel, C Kannel, RS Paffenbarger Jr, LA Cupples Heart rate and cardiovascular mortality: the Framingham Study Am Heart J 113 1987 1489 1494 (Pubitemid 17092823)